Top

Cancer Chemotherapy and Pharmacology

Published in:

01-12-2011 | Original Article

Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials

Authors: Daniel Binder, Ralf-Harto Hübner, Bettina Temmesfeld-Wollbrück, Peter Schlattmann

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2011

Abstract

Purpose

The combination of docetaxel and gemcitabine was tested in several studies in patients with lung, breast, and pancreatic cancers and other tumor entities. Some studies reported cases of severe or even fatal pulmonary toxicity that led to early termination of some trials. We created a meta-analysis model of published studies to identify explanatory factors for docetaxel–gemcitabine-dependent pulmonary toxicity.

Methods

We searched MEDLINE/Pubmed, EMBASE, and Cochrane Clinical Trials database for prospective full-text studies that used a schedule of docetaxel and gemcitabine to treat a malignant disease. We performed a meta-analysis for proportions using the arcsine transformation and a meta-regression using a generalized linear mixed model based on a binomial distribution and a logit link.

Results

We included 103 trials with 113 treatment arms comprising 5,065 patients (major entities included non-small cell lung cancer (n = 2,550), breast cancer (n = 1,119), pancreatic cancer (n = 466), and urothelial cancer (n = 161)). For the incidence of severe lung toxicity (common toxicity criteria [CTC] grades 3–5), we found a combined estimate of 2.70% (95% CI 2.26, 3.14). The estimate for the proportion of fatal cases was 0.35% (95% CI 0.21, 0.58).

We found that the sequence of the chemotherapy schedule had no influence on the incidence of severe pulmonary adverse events (F-test F = 0.65, df = 3,113, P = 0.58) nor did the study phase, treatment line or ethnicity of the participants. We found that patients with breast cancer, compared to lung cancer patients, developed severe lung toxicity less frequently (OR = 0.18, 95% CI (0.09, 0.36)).

Conclusion

We could not demonstrate that a particular chemotherapy sequence of docetaxel–gemcitabine is associated with excess pulmonary toxicity. Patients with lung cancer are at a higher risk for severe pulmonary side effects with docetaxel–gemcitabine than are patients with breast cancer.

Grande C, Villanueva MJ, Huidobro G, Casal J (2007) Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment. Clin Transl Oncol 9:578–581PubMedCrossRef

Alsamarai S, Charpidou AG, Matthay RA, Confeld D, Syrigos KN, Saif MW (2009) Pneumonitis related to docetaxel: case report and review of the literature. In Vivo 23:635–637

Merad M, Le Cesne A, Baldeyrou P, Mesurolle B, Le Chevalier T (1997) Docetaxel and interstitial pulmonary injury. Ann Oncol 8:191–194PubMedCrossRef

Nagata S, Ueda N, Yoshida Y, Matsuda H, Maehara Y (2010) Severe interstitial pneumonitis associated with the administration of taxanes. J Infect Chemother 16:340–344PubMedCrossRef

Galvão FH, Pestana JO, Capelozzi VL (2010) Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma. Cancer Chemother Pharmacol 65:607–610PubMedCrossRef

Pavlakis N, Bell DR, Millward MJ, Levi JA (1997) Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 80:286–291PubMedCrossRef

Roychowdhury DF, Cassidy CA, Peterson P, Arning M (2002) A report on serious pulmonary toxicity associated with gemcitabine-based therapy. Invest New Drugs 20:311–315PubMedCrossRef

Schwarte S, Wagner K, Karstens JH, Bremer M (2007) Radiation recall pneumonitis induced by gemcitabine. Strahlenther Onkol 183:215–217PubMedCrossRef

Moher D, Liberati A, Tetzlaff J, Altman DG, Altman DG for the PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535PubMedCrossRef

10.

Rücker G, Schwarzer G, Carpenter J, Olkin I (2009) Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta-analysis with zero cells. Stat Med 28:721–738PubMedCrossRef

11.

Schwarzer G (2010) meta: Meta-Analysis with R. R package version 1.1-8. http://CRAN.R-project.org/package=meta

12.

Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMedCrossRef

13.

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRef

14.

Agelaki S, Veslemes M, Syrigos K et al (2004) Hellenic Oncology Research Group. A multicenter phase II study of the combination of gemcitabine and docetaxel in previously treated patients with small cell lung cancer. Lung Cancer 43:329–333PubMedCrossRef

15.

Albertsson M, Johansson B, Friesland S et al (2007) Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. Med Oncol 24:407–412PubMedCrossRef

16.

Alexopoulos A, Tryfonopoulos D, Karamouzis MV et al (2004) Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer. Ann Oncol 15:95–99PubMedCrossRef

17.

Ardavanis A, Tryfonopoulos D, Alexopoulos A, Kandylis C, Lainakis G, Rigatos G (2005) Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study. Br J Cancer 92:645–650PubMedCrossRef

18.

Bhargava P, Marshall JL, Fried K et al (2001) Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer. Cancer Chemother Pharmacol 48:95–103PubMedCrossRef

19.

Binder D, Schweisfurth H, Grah C et al (2007) Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial. Cancer Chemother Pharmacol 60:143–150PubMedCrossRef

20.

Boukovinas I, Souglakos J, Hatzidaki D et al (2009) Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: a multicenter phase II study. Lung Cancer 63:77–82PubMedCrossRef

21.

Brandi M, Vici P, Lopez M et al (2004) Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study. Semin Oncol 31:13–19PubMedCrossRef

22.

Brugnatelli S, Danova M, De Bella MT, Vaglica M, Manuguerra G, Riccardi A, Palmeri S (2002) Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study. Oncology. 62:33–38PubMedCrossRef

23.

Casal J, Amenedo M, Mel JR et al (2007) Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study. Cancer Chemother Pharmacol 60:725–732PubMedCrossRef

24.

Cascinu S, Gasparini G, Catalano V et al (1999) A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann Oncol 10:1377–1379PubMedCrossRef

25.

Chan S, Romieu G, Huober J et al (2009) Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol 27:1753–1760PubMedCrossRef

26.

Chen YM, Perng RP, Lin WC, Wu HW, Tsai CM, Whang-Peng J (2002) Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. Am J Clin Oncol 25:509–512PubMedCrossRef

27.

Cobo M, Isla D, Massuti B et al (2007) Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 25:2747–2754PubMedCrossRef

28.

Cobo M, Gutiérrez V, Alcaide J et al (2007) A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status. Lung Cancer 56:255–262PubMedCrossRef

29.

De Castro J, Lorenzo A, Morales S et al (2005) Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma. Cancer Chemother Pharmacol 55:197–202PubMedCrossRef

30.

Dreicer R, Manola J, Schneider DJ et al (2003) Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group. Cancer 97:2743–2747PubMedCrossRef

31.

Dumez H, Martens M, Selleslach J et al (2007) Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study. Anticancer Drugs 18:211–218PubMedCrossRef

32.

Dumez H, Louwerens M, Pawinsky A et al (2002) The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors. Anticancer Drugs 13:583–593PubMedCrossRef

33.

Dunsford ML, Mead GM, Bateman AC, Cook T, Tung K (1999) Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol 10:943–947PubMedCrossRef

34.

Esteban E, Villanueva N, Muñiz I et al (2008) Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study. Invest New Drugs 26:67–74PubMedCrossRef

35.

Estévez LG, Sánchez-Rovira P, Dómine M et al (2007) Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study. Clin Transl Oncol 9:317–322PubMedCrossRef

36.

Fountzilas G, Nicolaides C, Bafaloukos D et al (2000) Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study. Cancer Invest 18:503–509PubMedCrossRef

37.

Fountzilas G, Dafni U, Dimopoulos MA et al (2009) A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat 115:87–99PubMedCrossRef

38.

Galetta D, Gebbia V, Giotta F et al (2002) Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale. Lung Cancer 38:79–84PubMedCrossRef

39.

Ganjoo KN, Gordon MS, Sandler AB et al (2002) A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: a Hoosier Oncology Group Study. Oncology 62:299–304PubMedCrossRef

40.

Georgoulias V, Kouroussis C, Androulakis N et al (1999) Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial. J Clin Oncol 17:914–920PubMed

41.

Georgoulias V, Ardavanis A, Tsiafaki X et al (2005) Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 23:2937–2945PubMedCrossRef

42.

Georgoulias V, Androulakis N, Kotsakis A et al (2008) Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer 59:57–63PubMedCrossRef

43.

Gitlitz BJ, Baker C, Chapman Y et al (2003) A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer 98:1863–1869PubMedCrossRef

44.

Hainsworth JD, Burris HA 3rd, Billings FT 3rd, Bradof JE, Baker M, Greco FA (2001) Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: phase II trials of the Minnie Pearl Cancer Research Network. Cancer 92:2391–2398PubMedCrossRef

45.

Hainsworth JD, Erland JB, Barton JH et al (2003) Combination treatment with weekly docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients and patients with poor performance status: results of a Minnie Pearl Cancer Research Network phase II trial. Clin Lung Cancer 5:33–38PubMedCrossRef

46.

Hainsworth JD, Carrell D, Drengler RL, Scroggin C Jr, Greco FA (2004) Weekly combination chemotherapy with docetaxel and gemcitabine as first-line treatment for elderly patients and patients with poor performance status who have extensive-stage small cell lung carcinoma: a Minnie Pearl Cancer Research Network phase II trial. Cancer 100:2437–2441PubMedCrossRef

47.

Hainsworth JD, Spigel DR, Farley C et al (2007) Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer 110:2027–2034PubMedCrossRef

48.

Hejna M, Kornek GV, Raderer M et al (2000) Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor. Cancer 89:516–522PubMedCrossRef

49.

Hensley ML, Maki R, Venkatraman E et al (2002) Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 20:2824–2831PubMedCrossRef

50.

Hensley ML, Blessing JA, Mannel R, Rose PG (2008) Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 109:329–334PubMedCrossRef

51.

Hensley ML, Ishill N, Soslow R et al (2009) Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: results of a prospective study. Gynecol Oncol 112:563–567PubMedCrossRef

52.

Hirsh V, Whittom R, Desjardins P et al (2004) Docetaxel and Gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): a phase II multicenter trial. Lung Cancer 46:113–118PubMedCrossRef

53.

Huang CH, Millenson MM, Sherman EJ et al (2008) Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapy. J Thorac Oncol 3:1032–1038PubMedCrossRef

54.

Ibrahim T, Zoli W, Frassineti GL et al (2005) Innovative sequence of docetaxel-gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: a phase I study. Lung Cancer 47:261–267PubMedCrossRef

55.

Israel V, Tagawa ST, Snyder T, Jeffers S, Raghavan D (2004) Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC). Invest New Drugs 22:291–297PubMedCrossRef

56.

Itani Y, Hosokawa K, Ito K et al (2009) A phase I/II study of docetaxel and gemcitabine combination for chemotherapy-resistant ovarian cancer. Anticancer Res 29:1521–1526PubMed

57.

Jacobs AD, Otero H, Picozzi VJ Jr, Aboulafia DM (2004) Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma. Cancer Invest 22:505–514PubMedCrossRef

58.

Kakolyris S, Papadakis E, Tsiafaki X et al (2001) Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study. Lung Cancer 32:179–187PubMedCrossRef

59.

Kalmadi S, McNeill G, Davis M, Peereboom D, Adelstein D, Mekhail T (2006) Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer. Med Oncol 23:507–513PubMedCrossRef

60.

Katakami N, Takiguchi Y, Yoshimori K et al (2006) Docetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma: a randomized phase II study by the Japan Lung Cancer Cooperative Clinical Study Group. J Thorac Oncol 1:447–453PubMedCrossRef

61.

Kawamura M, Eguchi K, Izumi Y et al (2007) Phase II trial of gemcitabine and docetaxel in patients with completely resected stage IIA-IIIA non-small-cell lung cancer. Cancer Chemother Pharmacol 60:495–501PubMedCrossRef

62.

Khoo KS, Manzoor Zaidi SH, Srimuninnimit V et al (2006) Gemcitabine and split-dose paclitaxel or docetaxel in metastatic breast cancer: a randomised phase II study. Eur J Cancer 42:1797–1806PubMedCrossRef

63.

Kornek GV, Haider K, Kwasny W et al (2002) Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor. Clin Cancer Res 8:1051–1056PubMed

64.

Kosmas C, Tsavaris N, Vadiaka M et al (2001) Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens. Cancer 92:2902–2910PubMedCrossRef

65.

Kouroussis C, Mavroudis D, Kakolyris S et al (2004) High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Lung Cancer 44:363–368PubMedCrossRef

66.

Labourey JL, Cupissol D, Calais G et al (2007) Docetaxel plus gemcitabine in recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study. Am J Clin Oncol 30:278–282PubMedCrossRef

67.

Laufman LR, Spiridonidis CH, Pritchard J et al (2001) Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial. Ann Oncol 12:1259–1264PubMedCrossRef

68.

LeCaer H, Fournel P, Jullian H et al (2007) An open multicenter phase II trial of docetaxel-gemcitabine in Charlson score and performance status (PS) selected elderly patients with stage IIIB pleura/IV non-small-cell lung cancer (NSCLC): the GFPC 02–02a study. Crit Rev Oncol Hematol 64:73–81PubMedCrossRef

69.

Lutz MP, Van Cutsem E, Wagener T et al (2005) Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group. J Clin Oncol 23:9250–9256PubMedCrossRef

70.

Maki RG, Wathen JK, Patel SR et al (2007) Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 25:2755–2763PubMedCrossRef

71.

Matsui K, Hirashima T, Nitta T et al (2005) A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer. Jpn J Clin Oncol 35:181–187PubMedCrossRef

72.

Mavroudis D, Malamos N, Alexopoulos A et al (1999) Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group. Ann Oncol 10:211–215PubMedCrossRef

73.

Mavroudis D, Malamos N, Polyzos A et al (2004) Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study. Oncology 67:250–256PubMedCrossRef

74.

Mekhail T, Hutson TE, Elson P et al (2003) Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies. Cancer 97:170–178PubMedCrossRef

75.

Meyer F, Lueck A, Hribaschek A, Lippert H, Ridwelski K (2004) Phase I trial using weekly administration of gemcitabine and docetaxel in patients with advanced pancreatic carcinoma. Chemotherapy 50:289–296PubMedCrossRef

76.

Neri B, Vannini L, Giordano C et al (2007) Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study. Anticancer Drugs 18:1207–1211PubMedCrossRef

77.

Neubauer MA, Garfield DH, Kuerfler PR et al (2005) Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer. Lung Cancer 47:121–127PubMedCrossRef

78.

Niho S, Kubota K, Goto K et al (2003) Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial. Cancer Chemother Pharmacol 52:19–24PubMedCrossRef

79.

Novello S, Falcone A, Crinò L et al (2009) Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer. Lung Cancer 66:327–332PubMedCrossRef

80.

O’Shaughnessy JA, Pluenneke R, Sternberg J, Khandelwal P, Ilegbodu D, Asmar L (2006) Phase II trial of weekly docetaxel/gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer 6:505–510PubMedCrossRef

81.

Pallis AG, Agelidou A, Papakotoulas P et al (2006) A multicenter phase II study of sequential vinorelbine and cisplatin followed by docetaxel and gemcitabine in patients with advanced non-small cell lung cancer. Lung Cancer 52:165–171PubMedCrossRef

82.

Palmeri S, Vaglica M, Spada S et al (2005) Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study. Oncology 68:438–445PubMedCrossRef

83.

Papadimitriou CA, Kalofonos H, Zagouri F et al (2009) Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic Co-Operative Oncology Group. Oncology 77:212–216PubMedCrossRef

84.

Park SH, Hong J, Kim YS et al (2008) Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer. Lung Cancer 62:72–77PubMedCrossRef

85.

Passardi A, Cecconetto L, Dall’agata M et al (2008) Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer. J Transl Med 6:65PubMed

86.

Pelegrí A, Calvo L, Antón A et al (2005) Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: final results of a phase II trial. Clin Breast Cancer 6:433–438PubMedCrossRef

87.

Pipas JM, Barth RJ Jr, Zaki B et al (2005) Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. Ann Surg Oncol 12:995–1004PubMedCrossRef

88.

Poole ME, Bernard SA, Churchel MA et al (2003) A phase I study of gemcitabine and docetaxel for advanced stage solid tumors. Cancer Invest 21:350–354PubMedCrossRef

89.

Popa IE, Stewart K, Smith FP, Rizvi NA (2002) A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma. Cancer 95:1714–1719PubMedCrossRef

90.

Pouessel D, Culine S, Becht C et al (2004) Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Cancer 100:1257–1261PubMedCrossRef

91.

Pujol JL, Breton JL, Gervais R et al (2005) Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 16:602–610PubMedCrossRef

92.

Ralli M, Tourkantonis I, Makrilia N et al (2009) Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study. Anticancer Res 29:3441–3444PubMed

93.

Rebattu P, Quantin X, Ardiet C et al (2001) Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer. Lung Cancer 33:277–287PubMedCrossRef

94.

Riccardi A, Brugnatelli S, Danova M et al (2006) Weekly docetaxel and gemcitabine following docetaxel plus epirubicin or vinorelbine as first-line treatment of metastatic breast cancer: results of a multicenter phase II study. Tumori 92:6–12PubMed

95.

Ridwelski K, Fahlke J, Kuhn R et al (2006) Multicenter phase-I/II study using a combination of gemcitabine and docetaxel in metastasized and unresectable, locally advanced pancreatic carcinoma. Eur J Surg Oncol 32:297–302PubMedCrossRef

96.

Rischin D, Boyer M, Smith J et al (2000) A phase I trial of docetaxel and gemcitabine in patients with advanced cancer. Ann Oncol 11:421–426PubMedCrossRef

97.

Rocha Lima CM, Rizvi NA, Zhang C et al (2004) Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC. Ann Oncol 15:410–418PubMedCrossRef

98.

Rubio JC, Vázquez S, Vázquez F et al (2009) A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma. Cancer Chemother Pharmacol 64:379–384PubMedCrossRef

99.

Ryan DP, Lynch TJ, Grossbard ML et al (2000) A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors. Cancer 88:180–185PubMedCrossRef

100.

Ryan DP, Kulke MH, Fuchs CS et al (2002) A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer 94:97–103PubMedCrossRef

101.

Schneider BP, Ganjoo KN, Seitz DE et al (2003) Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study. Oncology 65:218–223PubMedCrossRef

102.

Shepard RC, Levy DE, Berlin JD et al (2004) Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology group. Oncology 66:303–309PubMedCrossRef

103.

Sherman WH, Fine RL (2001) Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas. Oncology 60:316–321PubMedCrossRef

104.

Skarlos DV, Dimopoulos AM, Kosmidis P et al (2003) Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group. Lung Cancer 41:107–111PubMedCrossRef

105.

Spiridonidis CH, Laufman LR, Jones J, Rhodes VA, Wallace K, Nicol S (1998) Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies. J Clin Oncol 16:3866–3873PubMed

106.

Spiridonidis CH, Laufman LR, Carman L et al (2001) Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial. Ann Oncol 12:89–94PubMedCrossRef

107.

Stathopoulos GP, Mavroudis D, Tsavaris N et al (2001) Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 12:101–103PubMedCrossRef

108.

Syrigos KN, Dannos I, Dionellis G et al (2005) Bi-weekly administration of docetaxel and gemcitabine as first-line therapy for non-small cell lung cancer: a phase II study. Anticancer Res 25:3489–3493PubMed

109.

Syrigos KN, Karapanagiotou E, Charpidou A et al (2007) Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer: a phase II study. J Chemother 19:438–443PubMed

110.

Syrigos KN, Konstantinou M, Sepsas E et al (2007) Biweekly administration of docetaxel and gemcitabine as adjuvant therapy for stage II and IIIA non-small cell lung cancer: a phase II study. Anticancer Res 27:2887–2892PubMed

111.

Takeda K, Negoro S, Tamura T et al (2009) Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). Ann Oncol 20:835–841PubMedCrossRef

112.

Tas F, Demir C, Camlica H, Ustuner Z, Topuz E (2004) Second-Line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II trial. Med Oncol 21:233–240PubMedCrossRef

113.

Tomova A, Bartsch R, Brodowicz T et al (2010) Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG). Breast Cancer Res Treat 119:169–176PubMedCrossRef

114.

Vasey PA, Atkinson R, Osborne R et al (2006) SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer. Br J Cancer 94:62–68PubMedCrossRef

115.

Veltkamp SA, Meerum Terwogt JM, van den Heuvel MM, van Boven HH, Schellens JH, Rodenhuis S (2007) Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel. Invest New Drugs 25:279–281PubMedCrossRef

116.

Vici P, Giotta F, DI Lauro L et al (2009) Multicenter phase II trial of first-line docetaxel/gemcitabine in advanced breast cancer pretreated with adjuvant anthracyclines. Anticancer Res 29:1841–1845PubMed

Title: Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials
Authors: Daniel Binder
Ralf-Harto Hübner
Bettina Temmesfeld-Wollbrück
Peter Schlattmann
Publication date: 01-12-2011
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 6/2011
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-011-1648-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2011

Translational research of a novel humanized epidermal growth factor receptor-related protein: a putative inhibitor of pan-ErbB

Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study

Pharmacokinetic evaluation of the vinorelbine–lapatinib combination in the treatment of breast cancer patients

Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer